|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.05.25 - 22:03
|
Personalis Reports First Quarter 2025 Financial Results (Business Wire)
|
|
|
Clinical test volume of 2,184 increased 52% sequentially
Pharma tests and services of $13.6 million increased 39% year-over-year
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended March 31, 2025, and provided recent business highlights.
Recent Business Highlights
Delivered 2,184 total molecular tests in the first quarter of 2025, an increase of 52%, compared with 1,441 tests delivered in the fourth quarter of 2024, signifying increasing adoption of Personalis' technology
Highlighted compelling performance of NeXT Personal for resectable Stage I-IV colorectal cancer (CRC) in a study of 71 patients with British Columbia Cancer and an oral presentation at the American Association for Cancer Research (AACR) in Chicago in April
100% of patients that eventually recurred were detected as ctDNA positive by NeXT Personal, prior to detection on imaging
87% of eventual clinical ...
|
|
|
22.04.25 - 12:03
|
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection (Business Wire)
|
|
|
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two oral presentations and a poster presentation featuring data for the company's NeXT Personal® ultrasensitive ctDNA assay for residual and recurrent cancer detection will be presented at the American Association for Cancer Research (AACR) Annual Meeting April 25-30, 2025 in Chicago, Illinois.
“Our collaborators are excited to present new data, including initial results from the VICTORI study where NeXT Personal is being used to identify residual and recurrent colorectal cancer in patients. With a more sensitive test, our goal is to improve patient outcomes by finding and treating colorectal cancer recurrence earlier. We are also thrilled that NeXT Personal results from the TRACERx collaboration, one of the largest ctDNA studies in early-stage lung cancer, will be presented at the meeting,” said Dr. Richard Chen, Chief Medical Officer and Executive Vice Presi...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07.01.25 - 22:03
|
Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue (Business Wire)
|
|
|
Full year revenue of ~$84.6 million represents a 15% year-over-year increase
Cash balance of ~$185.0 million expected to provide runway to cash flow break-evenFREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2024 and preliminary cash balance.
Preliminary Full Year 2024 Revenue
Revenue of approximately $84.6 million for the full year of 2024 compared with $73.5 million for the full year of 2023, an increase of 15%, and above the company's previous full year guidance range of $83.0 to $84.0 million
Revenue from pharma tests and services, enterprise sales, and other customers of approximately $77.2 million for the full year of 2024 compared with $64.1 million for the full year of 2023, an increase of 20%, despite revenue from Natera decreasing 20% to approximately $25.4 million for the full year of 2024
Revenue from population sequencing...
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
